Clinical Trials In Georgia
Discover hundreds of clinical trials in Georgia.
Search clinical trials in Georgia by city, condition or phase.
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Sponsor:
AstraZeneca
Location:
Code:
NCT06120491
Conditions
Metastatic Castration-Sensitive Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Saruparib
Placebo
Abiraterone Acetate
Darolutamide
Enzalutamide
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05621291
Conditions
B-All
Acute Lymphoblastic Leukemia
Eligibility Criteria
Sex: All
Age: 1 - 25
Healthy Volunteers: Not accepted
Interventions
NGS testing
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT04873362
Conditions
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Atezolizumab
Trastuzumab Emtansine
Placebo
Trastuzumab
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM
Sponsor:
Laboratoire français de Fractionnement et de Biotechnologies
Location:
Code:
NCT05695391
Conditions
Hemophilia
Eligibility Criteria
Sex: Male
Age: 12 - 65
Healthy Volunteers: Not accepted
Interventions
Coagulation Factor VIIa (Recombinant)
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Sponsor:
Bellus Health Inc. - a GSK company
Location:
Code:
NCT05599191
Conditions
Refractory Chronic Cough
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BLU-5937
Placebo
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Sponsor:
Edgewise Therapeutics, Inc.
Location:
Code:
NCT05291091
Conditions
Becker Muscular Dystrophy
Eligibility Criteria
Sex: Male
Age: 12 - 50
Healthy Volunteers: Not accepted
Interventions
Sevasemten 10 mg
Sevasemten 5 mg
Sevasemten 12.5 mg
Placebo
Multi-center Trial to Improve Nocturia and Sleep in Older Adults
Sponsor:
Atlanta VA Medical Center
Location:
Code:
NCT06110091
Conditions
Nocturia
Insomnia
Eligibility Criteria
Sex: All
Age: 60+
Healthy Volunteers: Not accepted
Interventions
Integrated Behavioral Therapy Program
Health Education Program
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Sponsor:
Alexion Pharmaceuticals, Inc.
Location:
Code:
NCT06291376
Conditions
Immunoglobulin A Nephropathy
IgAN
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ravulizumab
Placebo
A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS)
Sponsor:
Helius Medical Inc
Location:
Code:
NCT05437276
Conditions
Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS)
Eligibility Criteria
Sex: All
Age: 22 - 65
Healthy Volunteers: Not accepted
Interventions
PoNS®
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Sponsor:
RayzeBio, Inc.
Location:
Code:
NCT05477576
Conditions
GEP-NET
Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor Disease
Neuroendocrine Tumors
Carcinoid
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RYZ101
Everolimus
Sunitinib
Octreotide
Lanreotide